Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands
- 15 June 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 132 (26) , 8848-8849
Abstract
Selective delivery of antisense or siRNA oligonucleotides to cells and tissues via receptor-mediated endocytosis is becoming an important approach for oligonucleotide-based pharmacology. In most cases receptor targeting has been attained using antibodies or peptide-type ligands. Thus, there are few examples of delivering oligonucleotides using the plethora of small-molecule receptor-specific ligands that currently exist. In this report we describe a facile approach to the generation of mono- and multivalent conjugates of oligonucleotides with small-molecule ligands. Using the sigma-receptor ligand anisamide as an example, we describe conversion of the ligand to a phosphoramidite and direct incorporation of this moiety into the oligonucleotide by solid-phase DNA synthesis. We generated mono- and trivalent conjugates of anisamide with a splice switching antisense oligonucleotide (SSO) and tested their ability to modify splicing of a reporter gene (luciferase) in tumor cells in culture. The trivalent anisamide−SSO conjugate displayed enhanced cellular uptake and was markedly more effective than an unconjugated SSO or the monovalent conjugate in modifying splicing of the reporter. Significant biological effects were attained in the sub-100 nM concentration range.Keywords
This publication has 22 references indexed in Scilit:
- The Biological Effect of an Antisense Oligonucleotide Depends on Its Route of Endocytosis and TraffickingOligonucleotides, 2010
- The pharmacology of sigma-1 receptorsPharmacology & Therapeutics, 2009
- RNAi‐based therapeutics–current status, challenges and prospectsEMBO Molecular Medicine, 2009
- Biological Barriers to Therapy with Antisense and siRNA OligonucleotidesMolecular Pharmaceutics, 2009
- An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumorJournal of Controlled Release, 2008
- Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotidesNucleic Acids Research, 2008
- Efficient Oncogene Silencing and Metastasis Inhibition via Systemic Delivery of siRNAMolecular Therapy, 2008
- Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosisNucleic Acids Research, 2008
- Chemical modification: the key to clinical application of RNA interference?Journal of Clinical Investigation, 2007
- Cell-penetrating-peptide-based delivery of oligonucleotides: an overviewBiochemical Society Transactions, 2007